-+ 0.00%
-+ 0.00%
-+ 0.00%
CSPC Group (01093): Phase IB/II clinical trial of syH2051 combined with irinotecan liposomes for the treatment of advanced solid tumors was officially launched at the first research center in China
Share
Listen to the news

Zhitong Finance App News, Shiyao Group (01093) announced that the phase IB/II clinical trial of syh2051 and irinotecan liposomes developed by the group for the treatment of advanced solid tumors has been officially launched at the first research center in China.

This product is a highly selective ataxia-telangiectasia mutant gene protein kinase inhibitor. It is registered as a Class 1 chemical. This product selectively inhibits the activity of ATM kinase, a core component of the cellular deoxyribonucleic acid damage repair system, and can prevent tumor cell DNA damage repair.

The clinical trial initiated this time is a multi-center, open-designed phase IB/II clinical trial. It is planned to enroll patients with advanced solid tumors. The aim is to evaluate the safety and efficacy of this product in combination with irinotecan liposomes. Currently, the recruitment and screening of participants for this clinical trial is being actively promoted.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending